Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10466523rdf:typepubmed:Citationlld:pubmed
pubmed-article:10466523lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C0588058lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C0007102lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C0027627lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C0577559lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C1609982lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:10466523lifeskim:mentionsumls-concept:C0872169lld:lifeskim
pubmed-article:10466523pubmed:issue4lld:pubmed
pubmed-article:10466523pubmed:dateCreated1999-9-23lld:pubmed
pubmed-article:10466523pubmed:abstractTextFluorine-18-2-deoxy-2-fluoro-D-glucose (F-18 FDG) PET may be more suitable for follow-up after cancer treatment than other morphologic approaches, because it reflects tumor viability. A patient with abdominal lymph node metastases from colon cancer was followed by CT and F-18 FDG PET during chemotherapy. F-18 FDG PET tumor images changed in accordance with the clinical progress, whereas CT findings were relatively unchanged. This case clearly shows the utility of F-18 FDG PET for follow-up during cancer chemotherapy.lld:pubmed
pubmed-article:10466523pubmed:languageenglld:pubmed
pubmed-article:10466523pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:citationSubsetIMlld:pubmed
pubmed-article:10466523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10466523pubmed:statusMEDLINElld:pubmed
pubmed-article:10466523pubmed:monthAprlld:pubmed
pubmed-article:10466523pubmed:issn0363-9762lld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:FukudaHHlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:FujiwaraTTlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:YoshiokaTTlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:KanamaruRRlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:IdeJJlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:IwataRRlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:MurakawaYYlld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:IshiokaCClld:pubmed
pubmed-article:10466523pubmed:authorpubmed-author:GamoMMlld:pubmed
pubmed-article:10466523pubmed:issnTypePrintlld:pubmed
pubmed-article:10466523pubmed:volume24lld:pubmed
pubmed-article:10466523pubmed:ownerNLMlld:pubmed
pubmed-article:10466523pubmed:authorsCompleteYlld:pubmed
pubmed-article:10466523pubmed:pagination261-3lld:pubmed
pubmed-article:10466523pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:meshHeadingpubmed-meshheading:10466523...lld:pubmed
pubmed-article:10466523pubmed:year1999lld:pubmed
pubmed-article:10466523pubmed:articleTitleFDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy.lld:pubmed
pubmed-article:10466523pubmed:affiliationDepartment of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan. ytakashi@idac.tohoku.ac.jplld:pubmed
pubmed-article:10466523pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10466523pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10466523pubmed:publicationTypeCase Reportslld:pubmed
pubmed-article:10466523pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10466523lld:pubmed